pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
  1. pharmadog
  2. ›drugs
  3. ›ENV-308
drug
save

ENV-308

Phase 1updated 6mo ago
by Enveda Biosciences Inc
Phase 1
community read0 votes

indications

indications
Obesity

all catalysts(0)

nothing on the calendar yet

News(6)

  • 5 biggest venture capital raises of Q3 2026
    Venture capital continued to flow into biopharma in the third quarter, though experts pointed out that investors remained selective, preferring to put their money behind advanced and derisked asset…
    biospace · 1mo ago
  • Enveda, an AI drugmaker, banks $311M in venture funding
    Enveda, which is using AI tools to mine plants and microbes for drug prospects, has three candidates in human testing for immune diseases and obesity.
    biopharma_dive · 1mo ago
  • AI drug hunter Enveda raises $311M for late-stage obesity, inflammatory disease push
    Tech darling Enveda has raised a total of $845 million in the past six years. The latest funding round is intended to pave the way for an IPO someday.
    biospace · 1mo ago
  • Enveda reaps $311M series E to feed ambition to become a ‘household name’
    Enveda has raised a $311 million series E round, positioning the nature-derived drug discovery company to pursue its goal of becoming a household name over the next decade.
    fiercebiotech · 1mo ago
  • Enveda’s exercise-simulating obesity tablet clears early clinical test
    Touting an “exceptional” gastrointestinal safety profile for its oral obesity drug candidate in a study of healthy volunteers, Enveda plans to test the asset in people stopping GLP-1 treatment.
    biospace · 3mo ago
  • STAT+: A pill that mimics exercise? Early results on drug designed to maintain both weight loss and muscle mass
    Colorado biotech Enveda reports preliminary results on a drug to help people maintain weight loss after GLP-1 use. Just don't call it exercise in a pill.
    stat · 3mo ago
indication
Obesity
phase
phase_1
Data sources
ClinicalTrials.gov
last refreshed 1h ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?